PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

免疫疗法 医学 索拉非尼 肿瘤微环境 免疫系统 免疫检查点 肝细胞癌 PD-L1 癌症研究 肿瘤科 联合疗法 免疫学 内科学
作者
Qian Li,Jingjing Han,Yonglin Yang,Yu Chen
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:13: 1070961-1070961 被引量:177
标识
DOI:10.3389/fimmu.2022.1070961
摘要

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
椰汁发布了新的文献求助10
刚刚
Shengyuu完成签到,获得积分10
1秒前
linqishi发布了新的文献求助10
2秒前
材料打工人完成签到 ,获得积分10
2秒前
内向的发卡完成签到,获得积分10
3秒前
4秒前
蓝天发布了新的文献求助10
4秒前
科研通AI6.2应助冬日可爱采纳,获得10
5秒前
椰汁完成签到,获得积分10
6秒前
我勒个大豆这么好用完成签到,获得积分10
6秒前
6秒前
我是老大应助XrosGhost采纳,获得10
7秒前
7秒前
lizishu应助小格爱科研采纳,获得10
9秒前
彭同学发布了新的文献求助10
10秒前
SciGPT应助Ashley采纳,获得10
10秒前
CYPCYP发布了新的文献求助10
11秒前
耍酷雁卉发布了新的文献求助20
11秒前
12秒前
13秒前
14秒前
小二郎应助cxy采纳,获得10
14秒前
14秒前
Hello应助蓝天采纳,获得10
14秒前
14秒前
15秒前
15秒前
情怀应助陈灿劲采纳,获得10
15秒前
沉舟发布了新的文献求助10
18秒前
深情安青应助Richard采纳,获得10
19秒前
mljever完成签到,获得积分10
19秒前
XrosGhost发布了新的文献求助10
19秒前
ARESCI发布了新的文献求助10
20秒前
MoriZhang完成签到,获得积分10
20秒前
20秒前
hzhang发布了新的文献求助10
20秒前
青柠完成签到 ,获得积分10
21秒前
22秒前
22秒前
23秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
ズームレンズの光学設計に関する研究 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7277030
求助须知:如何正确求助?哪些是违规求助? 8898117
关于积分的说明 18816203
捐赠科研通 6949671
什么是DOI,文献DOI怎么找? 3206395
关于科研通互助平台的介绍 2377413
邀请新用户注册赠送积分活动 2181327